Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients:the Treatment In Morning versus Evening (TIME) study by Rorie, David A. et al.
                                                              
University of Dundee
Methods of a large prospective, randomised, open-label, blinded end-point study
comparing morning versus evening dosing in hypertensive patients
Rorie, David A.; Rogers, Amy; Mackenzie, Isla; Ford, Ian; Webb, David J.; Willams, Bryan;








Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Rorie, D. A., Rogers, A., Mackenzie, I. S., Ford, I., Webb, D. J., Willams, B., ... MacDonald, T. M. (2016).
Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus
evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. BMJ Open,
6(2), [e010313]. DOI: 10.1136/bmjopen-2015-010313
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Methods of a large prospective,
randomised, open-label, blinded
end-point study comparing morning
versus evening dosing in hypertensive
patients: the Treatment In Morning
versus Evening (TIME) study
David A Rorie,1 Amy Rogers,1 Isla S Mackenzie,1 Ian Ford,2 David J Webb,3
Bryan Willams,4 Morris Brown,5 Neil Poulter,6 Evelyn Findlay,1 Wendy Saywood,1
Thomas M MacDonald1
To cite: Rorie DA, Rogers A,
Mackenzie IS, et al. Methods






Treatment In Morning versus




▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-010313).
Received 22 October 2015
Revised 18 January 2016
Accepted 19 January 2016






Introduction: Nocturnal blood pressure (BP) appears
to be a better predictor of cardiovascular outcome than
daytime BP. The BP lowering effects of most
antihypertensive therapies are often greater in the first
12 h compared to the next 12 h. The Treatment In
Morning versus Evening (TIME) study aims to establish
whether evening dosing is more cardioprotective than
morning dosing.
Methods and analysis: The TIME study uses the
prospective, randomised, open-label, blinded end-
point (PROBE) design. TIME recruits participants by
advertising in the community, from primary and
secondary care, and from databases of consented
patients in the UK. Participants must be aged over
18 years, prescribed at least one antihypertensive
drug taken once a day, and have a valid email
address. After the participants have self-enrolled and
consented on the secure TIME website (http://www.
timestudy.co.uk) they are randomised to take their
antihypertensive medication in the morning or the
evening. Participant follow-ups are conducted after
1 month and then every 3 months by automated
email. The trial is expected to run for 5 years,
randomising 10 269 participants, with average
participant follow-up being 4 years. The primary end
point is hospitalisation for the composite end point of
non-fatal myocardial infarction (MI), non-fatal stroke
(cerebrovascular accident; CVA) or any vascular death
determined by record-linkage. Secondary end points
are: each component of the primary end point,
hospitalisation for non-fatal stroke, hospitalisation for
non-fatal MI, cardiovascular death, all-cause mortality,
hospitalisation or death from congestive heart failure.
The primary outcome will be a comparison of time to
first event comparing morning versus evening dosing
using an intention-to-treat analysis. The sample size
is calculated for a two-sided test to detect 20%
superiority at 80% power.
Ethics and dissemination: TIME has ethical
approval in the UK, and results will be published in a
peer-reviewed journal.
Trial registration number: UKCRN17071; Pre-
results.
INTRODUCTION
Nocturnal blood pressure (BP) has consist-
ently been found to be a better predictor of
cardiovascular outcome than daytime BP. As
the day:night BP ratio increases, cardiovascu-
lar risk appears to decrease.1–4 There is also
evidence to suggest that antihypertensive
drugs taken in the evening rather than in the
morning reduce nocturnal blood pressure to
a greater extent,5–7 and might have more
beneﬁt in hypertension alone8 9 hypertension
with renal disease10 11 and hypertension with
diabetes.12 A recent study that examined the
effect on nocturnal blood pressure of drugs
taken in the evening in participants with
Strengths and limitations of this study
▪ Use of technology including an electronic case
report form and record linkage to identify poten-
tial end points allows efficient data management.
▪ The open-label design provides good external
validity. The end-point committee is blinded to
treatment randomisation.
▪ Limitations include the generalisability of results
based on participants who have an email
address and are technologically literate.
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resistant hypertension found that bedtime dosing
resulted in signiﬁcantly lower 24 h means of systolic and
diastolic BP (by 4.1/1.5 mm Hg) and that this difference
between groups was driven by asleep BP (9.7/4.4 mm Hg
lower).13 The most recent and most compelling evi-
dence in favour of nocturnal dosing comes from the
Monitorización Ambulatoria para Predicción de Eventos
Cardiovasculares (MAPEC) study which randomly
assigned 2156 hypertensive patients to take all of their
antihypertensive drugs on awakening or to take one or
more of them at bedtime.14 15 All patients in this study
underwent ambulatory blood pressure monitoring
(ABPM) at baseline and yearly, and all wore wrist activity
metres to control for the effects of activity on BP and to
determine when participants were asleep.16 Participants
in the study who took one or more antihypertensive drugs
at bed-time had 68 cardiovascular events whereas those
who took all medication on awakening had 187 events; a
relative risk reduction of 64% (p<0.001). Forty-eight-hour
ABPM showed lower systolic BP (122.1 mm Hg morning
dosing vs 120.8 mm Hg evening dosing p=0.029) with
evening dosing and this difference was due to lower
asleep systolic blood pressure (116.1 mm Hg morning
dosing vs 110.9 mm Hg evening dosing, p<0.001). The
MAPEC study was limited in that it was not prospectively
powered, the process of randomisation was not reported,
and the end points included some unusual cardiovascular
events, and were not independently adjudicated.
Further studies are needed to establish the optimal
time of dosing for hypertensive patients.17 18 Therefore,
the present study aims to substantiate the ﬁndings of the
MAPEC study and test the hypothesis that nocturnal
dosing of antihypertensive medication reduces cardiovas-
cular events compared with conventional morning
dosing. Secondary questions will examine whether there
are any downsides to nocturnal dosing and if nocturnal
dosing is acceptable to patients, for example, whether
nocturnal dosing of diuretics causes unacceptable noc-
turia will be evaluated. Data will also be collected on




The Treatment In Morning versus Evening (TIME) study
is a prospective, randomised, open-label, blinded end-
point (PROBE) design19 controlled clinical trial. TIME
(http://www.timestudy.co.uk) builds on a successful
novel methodology to track patient outcome using infor-
mation technology (IT). The project will be conducted
on a secure web portal with patients signing up on-line
and being followed up by email and record-linkage to
national databases to identify hospitalisations and
deaths.20 21 End points will be detected by record-linkage
to hospitalisation, death certiﬁcation records and regular
email contacts with patients and nominated surrogates.
Primary or secondary care records and physicians will be
contacted for further data, if required (all patients must
consent to their medical records and physicians being
accessed or contacted). All end-point adjudication will
be blinded to dosing time and original medical records
will be retrieved for hospitalisation events to validate end
points. The schematics and ﬂow of the study can be seen
in ﬁgures 1 and 2. The TIME study underwent a pilot
phase between 2011 and 2014 to determine feasibility of
a full study. At that time the study was not adopted by
the UKCRN and so trial registration was not possible.
There were doubts as to the viability of the study being
conducted online and whether there would be sufﬁcient
recruitment uptake. Once the study was deemed sustain-
able, funding was in place, and the clinical trials net-
works adopted the study, it was prospectively registered
in ISCRTN and the pilot transferred to the full study.
Recruitment strategy
In an effort to recruit the necessary number of partici-
pants, the full study will seek to recruit by advertising to
hypertensive patients in the UK from primary care, sec-
ondary care and from databases of patients who have
previously consented to being contacted about potential
research projects. Collaborating general practitioners
(GPs) will bring this trial to the attention of all treated
hypertensive patients in their practices by sending letters
advertising the study. Secondary care clinics will also
send letters advertising the study to previous clinic atten-
dees and display advertising posters in appropriate
patient waiting areas. Databases of consented patients
will be utilised where appropriate, such as UK Biobank,22
Tayside Bioresource and GoShare,23 contacting patients
and advertise the study to them. The Database owners
will send approved letters on behalf of TIME. The inclu-
sion and exclusion criteria for TIME are listed in boxes 1
and 2. Potential study participants are invited to com-
plete an initial online study registration. This process
requires them to conﬁrm their eligibility against the
study inclusion and exclusion criteria before allowing
them to proceed and complete enrolment.
Intervention
Participants within the study are randomly allocated to
one of two dosing periods. Participants allocated to
morning dosing are advised to take all of their usual
blood pressure lowering medications between 6:00 and
Figure 1 Schematic diagram of study.
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10:00 throughout the study. Those allocated to evening
dosing are instructed to take all their blood pressure
lowering medications between 20:00 and midnight.
There is no other intervention in the study and partici-
pants continue to attend their usual GP or outpatient
clinic for routine hypertension follow-up.
Follow-up
Patients will be followed up after 1 month of being
assigned a randomised time of dosing, and then every
3 months. Contact will be made by automated email with
a reminder email sent 14 days later. If the follow-up has
still not been completed then 14 days after the ﬁrst email
Figure 2 TIME study flow diagram.
Box 2 TIME exclusion criteria
Exclusion criteria
1. Participants who take two times a day antihypertensive
therapy.
2. Participants who work shift patterns that include a night shift.
3. Participants who are unwilling to consent to:
A. Follow-up
B. Providing a surrogate to be contacted and/or
C. Their family practice releasing follow-up clinical data
D. Their physical case records abstracted if required
E. Their electronic case records searched and abstracted if
required
F. Their consent form to be copied to authorities from
whom the study team is requesting medical data.
4. Those participating in another clinical trial or who have done
in the past 3 months.
Box 1 TIME inclusion criteria
Inclusion criteria
▸ Both diagnosed and treated for hypertension (all forms) with
at least one antihypertensive drug.
▸ Age ≥18 years.
▸ Have a valid email address.
Rorie DA, et al. BMJ Open 2016;6:e010313. doi:10.1136/bmjopen-2015-010313 3
Open Access
group.bmj.com on December 22, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
reminder has been sent an email will be sent to the parti-
cipant’s surrogate asking them to respond as to the well-
being of the participant. As a last resort, telephone calls
to patients or primary care physicians can be used to
contact participants and to ask them to complete follow-
ups. Participants can enter follow-up data at any time
during the trial by logging into the secure website and
are not restricted to waiting for automated emails. A ﬁnal
record linkage will be performed 3 months after the end
of the trial in order to capture late recorded events and a
ﬁnal 3 months will be spent ﬁnalising adjudications,
locking the database and carrying out the analysis.
Consenting participants
Patients will be required to ﬁll in an electronic consent
form (ﬁgure 3). The consent form will consist of check
boxes to attest to consent for each aspect of the trial. A
ﬁnal check box will be marked ‘I have read, answered
and understood all of the above questions and under-
stand this is an electronic signature’. The consent form
will record the participant’s internet protocol (IP)
address along with their email address and a time stamp
of when the form was electronically submitted. The
consent form will be sent to participants electronically
in portable document format (PDF) format for their
own records. The decision of a participant to participate
in clinical research is voluntary and will be based on a
clear understanding of what is involved. A patient infor-
mation sheet will be available on the TIME website with
detailed information about the trial. The consent
process will be conducted by participants and entirely
via the study website, without the active participation of
study personnel. Participants will be given opportunities
to clarify any points they do not understand, and to ask
for more information by using a ‘Contact Us’ link, or
the free phone telephone number, on the study website.
Withdrawal
Participants will be free to withdraw from the TIME
study at any point. A participant can withdraw from:
▸ Taking medication according to the time of
randomisation.
▸ Receiving further follow-up emails.
▸ Follow-up of their outcome by record linkage, con-
tacting their surrogate or by contacting their family
doctor.
Part of the objective of this study is to determine if sub-
jects can continue to take medication at their randomly
allocated time, and indeed, we expect that a proportion
of participants will withdraw from taking medication at
their allocated time. We shall evaluate the withdrawal
rate and record reported reasons for their withdrawal.
RANDOMISATION
Computer randomisation
Randomisation is carried out centrally using randomly
generated bits (0 and 1 s) which are then allocated to
participants (0=morning, 1=evening) sequentially.
Randomised status is conﬁrmed by automated email
sent to the participant.
Treatment allocation
Participants are randomised to take their antihyperten-
sive medications in the morning (range 6:00–10:00) or
in the evening (range 20:00–midnight). Treatment allo-
cation is not made available to treating physicians unless
there is a speciﬁc individual clinical need.
Study population
Hypertensive patients aged 18 or over, in the UK,
prescribed one or more once daily antihypertensive




The primary end point is ﬁrst occurrence after random-
isation of vascular death or hospitalisation for the com-
posite end point of non-fatal MI or non-fatal stroke, in
keeping with major cardiovascular disease (CV) end-
point trials.24
Secondary end points
Secondary end points (in rank order) will include:
▸ Each component of the primary end point:
– Hospitalisation for non-fatal stroke
– Hospitalisation for non-fatal MI
– Cardiovascular death
▸ All-cause mortality
▸ Hospitalisation or death from congestive heart
failure.
End-point adjudication
End points will be adjudicated by an independent end-
point committee who will be blind to dosage time alloca-
tion. Hospitalisation data will be retrieved in collabor-
ation with the medical records departments. Copies of
the patient consent forms will be supplied to facilitate
this process. The records will be processed, abstracted
and suitably redacted to produce anonymised end-point
packages for the end-point committee. This committee
will have due regard of the published consensus diagnos-
tic criteria for myocardial infarction,1 25 stroke,26 vascu-
lar death, and heart failure.27
Adverse events
Recording of serious adverse events (AEs) will focus on
deaths and hospital admissions as these will be obtained
systematically by record linkage. The present study will
collect only non-serious AEs associated with changing
the time of dosing. Follow-up (ﬁgure 4) and withdrawal
(ﬁgure 5) questionnaires include a mix of open and
closed questions regarding medical events and potential
AEs. In the case of an AE, patients will judge whether
4 Rorie DA, et al. BMJ Open 2016;6:e010313. doi:10.1136/bmjopen-2015-010313
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Figure 3 Consent form.
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Figure 4 Follow-up form.
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they are happy to continue taking treatment at the time
randomised or whether they wish to change or revert to
the alternative time of dosing, or, whether they wish to
discontinue the study.
An additional reason for carrying out the study is to
determine whether participants can tolerate taking
medication in the evening. This is prospectively mea-
sured. Participants self-report AEs associated with dosing
time and whether nocturnal diuretic dosing has been
acceptable to them and whether falls and fractures are
increased as a potential surrogate for nocturnal hypoten-
sive events.
Statistics
The primary outcome will be a comparison of time to
ﬁrst event comparing morning versus evening dosing
allocation. This outcome will be analysed using a Cox
proportional hazards model including treatment group
Figure 5 Withdrawal form.
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as a covariate. The p value for the treatment effect will
be based on the Wald statistic. Point estimates and
95% CIs will be calculated for the treatment effect
HR. Time to event curves will be based on cumulative
incidence functions. Time to event secondary out-
comes will be analysed using similar methods. The pro-
portionality of hazards assumptions will be assessed
using Cox models including treatment group by log
(time) interactions.
Serious AEs and AEs will be tabulated by treatment
group by system organ class and preferred term. All
main analyses will be on an intention-to-treat basis.
Data collection and retention
This study will capture data directly from patients or their
nominated surrogates and by record linkage to hospitali-
sations and deaths. Consent will be gathered from
patients to have access to their healthcare records, diag-
nostic or death data, their acute care summary, their
paper or electronic records, their paper or electronic
primary care records, and, permission to contact their
physicians for further data. Data will be validated at point
of entry into the TIME database and at regular intervals
during the study. Data will be held securely within the
Medicines Monitoring Unit (MEMO) at Ninewells
Hospital and Medical School. To enable evaluations and/
or audits, the investigators will keep records, including
the identity of all participating patients, all original
informed consent data, AE data and any source docu-
ments. The records will be securely retained and archived
by the study sponsor according to ICH, GCP and local
regulations. Participating individuals will be able to have
sight of their own data on request and will be allowed to
comment on perceived inaccuracies therein.
Data protection
The study will comply with the requirements of the Data
Protection Act 1998 with regard to the collection,
storage, processing and disclosure of personal informa-
tion and will uphold the Act’s core principles. Access to
collated participant data will be restricted to appropriate
study staff. Published results will not contain any per-
sonal data that could allow identiﬁcation of individual
participants.
Sample size: evidence of feasibility and power calculation
For a two-sided test to detect a HR of 0.8 for the primary
outcome (evening dosing vs morning dosing) at 80%
power, 631 events are needed. Based on the anticipated
proﬁle of participants, a trial with an average 4-year
follow-up period would need to randomise 9780 partici-
pants. Since the primary analysis is intention to treat and
because few participants are likely to withdraw consent
for record-linkage follow-up, only relatively minor (<5%)
inﬂation of the 9780 participants is required to compen-
sate. A target of 10 269 participants will be randomised.
Note that falling cardiovascular event rates in the UK
may require a revision of the sample size.
SUBSTUDIES
Home BP substudy
Randomised members of the TIME study are asked,
during enrolment, if they are prepared to participate in
a substudy and submit home BP readings. Participants
who own their own home BP monitor are asked to
record and submit BP readings at baseline and then
regularly throughout the study. All types and brands of
home BP monitors are accepted. A comparison of data
collected from non-validated versus validated equipment
will be conducted. Participants are issued with instruc-
tions to take and submit three sets of readings, morning
and evening, for 4–7 days. Speciﬁc advice is provided
about how to take the measurements in accordance with
National Institute for Health and Care Excellence guide-
lines. The results will demonstrate the effect on home
BP of morning versus evening dosing and may help val-
idate adherence to nocturnal dosing.
Cognitive function substudy
Hypertension has been shown to be a predictor of mild
cognitive decline.28 29 Previous studies have indicated
that, particularly at age ≥70 years,30 31 BP-lowering has
relatively little impact on the rate of cognitive decline;
but most trials used morning dosing only. The main
purpose of cognitive testing in TIME will be to detect
temporal change, particularly any sustained reduction in
performance, associated with time of antihypertensive
dosing. We propose to use combined telephone testing
with the Montreal Cognitive Assessment Test and the
Trends in Cognitive Sciences29 to assess cognitive func-
tion in consenting participants in the TIME trial.
Previous experience shows that testing takes between 15
and 30 min and is well tolerated by patients.
Genetics substudy
All participants will be asked if they are prepared to
consent to participate in a genetics substudy where their
DNA will be bio-banked for possible future genetic
studies. Participants who consent will be asked to
provide a cheek swab or saliva collection by post.
COMPETING STUDIES
We are not aware of any competing studies that would
conﬂict with the TIME study.
Early stopping
The Independent Data and Safety Monitoring Committee
(IDMC) will review un-blinded study results on a regular
basis. Taking a balanced view of all accumulated data,
levels of statistical signiﬁcance and the seriousness of
events the IDMC might recommend stopping of the study
because of an excess of serious AEs in the evening dosing
group. The IDMC will also have the opportunity to make a
recommendation of early stopping because of overwhelm-
ing evidence of beneﬁt from evening dosing based on
interim analyses after approximately 50% and 75% of the
8 Rorie DA, et al. BMJ Open 2016;6:e010313. doi:10.1136/bmjopen-2015-010313
Open Access
group.bmj.com on December 22, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
target number of adjudicated study outcomes have been
observed. Overwhelming evidence of beneﬁt is deﬁned as
evidence of beneﬁt of evening dosing versus morning
dosing (p<0.001).
ETHICS AND DISSEMINATION
Steering committee and IDMC
The TIME steering committee oversees the appropriate
scientiﬁc and ethical conduct of the trial, provides advice
to the Study Sponsor, advises on the conduct and analysis
of the study, and approves all publications and substudies.
The Committee will operate through meetings, telecon-
ferences and emailings. The Steering Committee will be
made up of invited experts, the Chief Investigator, the
chair of the end-point Committee plus the coapplicants.
The Steering Committee will meet at least annually.
The IDMC is completely independent and comprises
experts in the ﬁeld including clinicians with experience
in hypertension and an expert trial statistician. The com-
mittee receives un-blinded data and has the power to
recommend modiﬁcations to the conduct of the study,
including early discontinuation based on a risk/beneﬁt
assessment of the study data. It will meet at least annu-
ally and report to the Steering Committee.
Sponsorship: monitoring, audit, quality control and quality
assurance
The study sponsor is the University of Dundee, who are
responsible for monitoring and quality assurance.
MEMO has conducted independent penetration testing
of the TIME website and the Tayside Medical Science
Centre (TASC) is assisting MEMO in ensuring quality
control for the study. The pilot study was funded by the
British Hypertension Society; the full trial is funded by
the British Heart Foundation.
Protocol amendments
Changes in research activity, except those necessary to
remove an apparent, immediate hazard, will be reviewed
and approved by the Chief Investigator and Sponsor.
Amendments to the protocol will be submitted in
writing for approval by the appropriate regulatory and
ethical authorities prior to implementation.
Collaborating investigators
Collaborating investigators will be responsible for
dealing with the local issues of bringing the trial to the
attention of possible participants either in clinics or in
primary care. Since all patients by their own volition
decide to go to the study website and sign up, the usual
investigator/study subject relationship is not present.
Confidentiality
All data will be held securely with restricted access.
Clinical information will not be released without the
written permission of the participant, except as
necessary for auditing by the sponsor, its designee, regu-
latory authorities or the research ethics committee.
Trial registration
TIME is registered as ISRCTN: 18157641 and with a
UKCRN ID: 17071. The trial is performed in line with
Good Clinical Practice guidelines and International
Society of Pharmacoepidemiology (ISPE) Good
Pharmacoepidemiology Practice Guidance.28
Dissemination
The results of the trial will be published in a peer-
reviewed scientiﬁc journal and made available to
participants.
DISCUSSION
The trial design of TIME allows a large study to be
undertaken efﬁciently and cost-effectively by maximising
the beneﬁts of modern technology, including use of an
electronic case report form and following up patients
using record linkage. All data are entered directly by
participants, thereby helping to reduce researcher time
and costs. Participant’s GPs are made aware of their par-
ticipation in the study but there is no signiﬁcant work-
load implication and GPs are not required to submit
data. The study allows participants to self-enrol, consent
and provide data in a secure online environment. The
TIME study has been awarded a grant from the BHF to
write to 300 000 patients across the UK to achieve its
target of randomising over 10 000 participants.
If the TIME study shows deﬁnite beneﬁts of dosing
antihypertensive medication in the evening rather than
the morning, this would represent the most cost-effective
advance in the treatment of hypertension and the pre-
vention of CV disease in recent years. TIME will also
establish whether participants can tolerate nocturnal
dosing and whether there are any AEs of nocturnal
versus morning dosing.
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